Displaying 1181 - 1200 of 1551
Generic Drug Marketers Settle FTC Charges
Piedmont Health Alliance Settles FTC Price-fixing Charges
With Conditions, FTC Allows Cephalons Purchase of CIMA, Protecting Competition for Breakthrough Cancer Pain Drugs
Announced Action for August 6, 2004
Southeastern New Mexico Physicians IPA, Inc., a corporation, and Barbara Gomez and Lonnie Ray, individually
A Roswell, New Mexico physicians’ association, Southeastern New Mexico Physicians IPA, settled charges that it and two of its employees entered into collective agreements among physician members on fees and refused to deal with health plans that did not accept the collective agreed-upon terms. According to the complaint, these practices increased the price of health care in the Roswell area. The consent order prohibits the IPA and its employees named in the consent from orchestrating agreements between physicians to negotiate with health insurance plans on behalf of any physician and deal or refuse to deal individually with any third party payer.
FTC Denies State Dental Boards Dismissal Motion on State Action Grounds
Resolving Anticompetitive Concerns, FTC Clears Sanofi-Synthlabos Acquisition of Aventis
FTC and DOJ Issue Report on Competition and Health Care
Announced Action for July 16, 2004
Andrx Pharmaceuticals, Inc. v. Kroger Co
Contact Lens Rule
New Mexico Physicians' Group Agrees to Settle FTC Price-Fixing Charges
Jackson, Tennessee Hospital Co. v. West Tennessee Healthcare, Inc
Announced Actions for May 25, 2004
Bristol-Myers Squibb Company, In the Matter of
Bristol-Myers Squibb Company (BMS) settled charges that it engaged in illegal business practices to delay the entry of three low price generic pharmaceuticals that would be in direct competition with three of its branded drugs. The complaint alleged that BMS purposely made wrongful listings in the Orange Book of the U.S. Food & Drug Administration and that it also paid a potential competitor over $70 million to delay the entry of its generic drug. The three drugs involved in the complaint are: Taxol (containing the active ingredient paclitaxel) – used to treat ovarian, breast, and lung cancers; Platinol (containing the active ingredient cisplatin) – used for the treatment of various forms of cancer; and BuSpar (containing the active ingredient buspirone) – used to manage anxiety disorders. To prevent recurrence of Bristol's pattern of alleged improper listings, the consent order eliminates Bristol's ability to obtain a 30-month stay on later-listed patents. By denying Bristol the benefit of the 30-month stay on later-listed patents, the order would reduce Bristol's incentive to engage in improper behavior before the PTO and the FDA to obtain and list a patent for the purpose of obtaining an unwarranted automatic 30-month stay.
Announced Action for May 11, 2004
Health Care Information and Competition conference
FTC Staff: Rhode Island Bills Would Raise Prices for Pharmaceuticals
Displaying 1181 - 1200 of 1551